New GST Rate For Medicines 2026: Latest Rate, Price, and Impact of GST 2.0

The GST 2.0 reforms, effective from 22 September 2025, mark the most significant tax update in the Indian pharmaceutical sector since 2017. Announced during the 56th GST Council meeting, these Next-Gen reforms introduce a simplified three-tier tax structure—5%, 18%, and 40%—with a focus on making healthcare more affordable.

Under the 2026 GST regime, nearly all categories of medicines have been moved to the 5% “Merit” slab, while essential life-saving treatments are fully exempt from GST.

Note: While most sanitary products were already exempt, the 2025 reform confirmed a ‘Nil’ GST rate for all clinical hygiene and baby care essentials.

The Indian pharmaceutical industry continues to be a global leader, often called the “Pharmacy of the World.” In 2026, its impact is more significant than ever, driven by:

• Export leadership: India produces over 20% of the world’s generic medicines by volume.
• Economic contribution: The sector is a major driver of national GDP and a key employer of highly skilled R&D professionals.
• Advancing health equity: With GST rates lowered to 5% or 0%, manufacturers can reduce MRPs, helping to cut out-of-pocket healthcare costs for ordinary citizens.

For a closer look at taxpayer identification in the pharmaceutical sector, explore the unique identification number under GST.

Impact of GST 2.0 on medicines

The 2025 GST rationalisation has created a “consumer-first” pricing environment, but it also presents a technical challenge for manufacturers known as the Inverted Duty Structure (IDS).

1. Lower Consumer prices: According to 2026 market data, a cardiac medicine that previously cost Rs. 1,120 under 12% GST now costs around ₹1,050, passing the 7% tax saving directly to patients.
2. Simplified compliance: Reducing the GST slab from 12% to 5% has minimised classification disputes between “medicaments” and “food supplements.”
3. The IDS challenge: While finished medicines attract 5% GST, many raw materials (Active Pharmaceutical Ingredients or APIs) are still taxed at 18%. This creates a build-up of Input Tax Credit (ITC) for companies. To address this, the government has introduced automated ITC refunds within 90 days, helping maintain liquidity in the sector.